PSPreksha Shahagadkar

Preksha Shahagadkar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Preksha Shahagadkar has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure 1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    FOCAD deletion is frequent in cancer and confers hyperdependence on the HBS1L–PELO complex. A, Frequency of co-deletion with MTAP of chromosome 9p genes in proximity to CDKN2A. B, sgRNA-level effects from a genome-wide CRISPR screen in FOCAD isogenic MIAPACA2 cells. Cells expressing FOCAD cDNA (FOCAD-positive) or an empty vector control (FOCAD-negative) were infected with a genome-wide sgRNA library and cultured for 14 days prior to gDNA isolation and next-generation sequencing. Data are shown as log2 fold change (log2FC) in FOCAD-negative vs. FOCAD-positive cells. Raw CRISPR screening data previously reported (24). C, Model for the therapeutic hypothesis underlying the synthetic lethal interaction between FOCAD inactivation and the HBS1L–PELO complex. (Created in part with BioRender, Nicholson, H E. (2023) https://BioRender.com/ralcu3s).

  • Open Access

    Figure 2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    Hit finding strategy and discovery of molecular glues that drive CRBN-dependent ternary complex formation and selective degradation of HBS1L over GSPT1. A, Schematic of the parallel screening strategy used to identify HBS1L molecular glues. Left, HiBiT-based cellular assay using CRISPR knock-in of HiBiT at the endogenous HBS1L locus to enable high-throughput measurement of target degradation. Right, TR-FRET ternary complex assay to detect ligand-induced proximity between CRBN and HBS1L. Compounds active in both assays were prioritized. (Created in part with BioRender, Teng, T. (2026) https://BioRender.com/14wx5zd; Teng, T. (2026) https://BioRender.com/3lkesgf) B, Structures and activity summary for an initial screening hit TNG-6266 and optimized TNG961 in cellular degradation and ternary complex formation assays. AC50 is not reported when Bmax < 50%; DC50 and AC50 values are corrected for media binding. C, Compound profiling across the HBS1L-HiBiT degradation assay and the HBS1L ternary complex formation (induced proximity) assay. Color indicates the degree of selectivity for HBS1L over GSPT1 with DC50 values corrected for media binding. D, Activity summary for TNG-4857, TNG-7535, and TNG-7326; DC50 and AC50 values are corrected for media binding. E, Binding of TNG-4857 (yellow) at the interface of HBS1L (green) and CRBN (blue) in the 2.6 Å resolution cryo-EM structure of the HBS1L–CRBN–DDB1 complex (PDB 11MR). Dashed lines indicate hydrogen bonds.

  • Open Access

    Figure 3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 mediates HBS1L–CRBN complex formation, leading to HBS1L degradation and FOCAD-dependent loss of viability. A, Cellular degradation of HBS1L and GSPT1 measured by HiBiT signal in 293T HBS1L-HiBiT and 293T GSPT1-HiBiT knock-in cell lines after 24 hours of treatment with the indicated concentrations of TNG961. Data are mean ± SD (N = 2 biological replicates; 2 technical replicates each). B, Live-cell degradation kinetics of HBS1L measured by HiBiT signal in 293T HBS1L-HiBiT knock-in cells over 12 hours following treatment with the indicated concentrations of TNG961. Data are mean ± SD (N = 2 biological replicates). C, TR-FRET ternary complex formation between CUL4A–RBX1–DDB1–CRBN and Avi-tagged HBS1L (red circles) or Avi-tagged GSPT1 (blue squares) in the presence of increasing concentrations of TNG961. Signal (%) is normalized to the CC-885–positive control well. Data are mean ± SD (N = 3 independent experiments; 2 technical replicates each). D, Cryo-EM structure (2.9 Å) of HBS1L (green) bound to the CRBN–DDB1 complex (blue and pink) in the presence of TNG961 (orange; PDB 10AY). E, Close-up surface view of TNG961 (orange) at the CRBN–HBS1L interface (PDB 10AY). The surface of HBS1L is depicted, and dashed lines indicate hydrogen bonds. F, Close-up surface view of CC-885 (purple) at the CRBN–GSPT1 interface (PDB 5HXB). The surface of GSPT1 is depicted.

  • Open Access

    Figure 4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 induces potent, selective CRBN-dependent degradation of HBS1L. A, Endogenous HBS1L degradation and PELO destabilization measured by Western blot after 24 hours of treatment with TNG961 in the indicated cell lines. The top dose was 10 µmol/L, tested as a 9-point, 3-fold dilution series. Representative images are from N = 2 biological replicates. B, CRBN dependence of HBS1L degradation and PELO destabilization assessed by Western blot after 24 hours of treatment with the indicated concentrations of TNG961 in parental and CRBN knockout (sgCRBN) MIAPACA2 cells. Representative images are from N = 2 biological replicates. C, Neddylation dependence assessed by Western blot after 24 hours of treatment with TNG961 alone or in combination with 100 nmol/L MLN4924 in MIAPACA2 cells. Representative images are from N = 2 biological replicates. D, Degron-loop dependence assessed by Western blot after 24 hours of treatment with the indicated concentrations of TNG961 in parental MIAPACA2 cells and in engineered lines expressing either HBS1L G625N (covering endogenous HBS1L knockout) or GSPT1 G575N (covering endogenous GSPT1 knockout). Representative images are from N = 3 biological replicates. E, Global quantitative proteomics in MM.1s cells after 6 hours of treatment with 500 nmol/L TNG961 or DMSO. Data are shown as relative protein abundance (TNG961/DMSO); HBS1L, PELO, and common IMiD neosubstrates are annotated. F, Western blot analysis of common CRBN neosubstrates after 24 hours of treatment with TNG961 at the indicated concentrations. Representative images are from N = 2 biological replicates.

  • Open Access

    Figure 6 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 induces translational arrest and activates ER stress and the UPR selectively in FOCAD-null cells. A, Translation assessed by puromycin incorporation in FOCAD isogenic MIAPACA2 cells after 48 hours of treatment with the indicated concentrations of TNG961. Puromycin immunoblot intensity was normalized to Ponceau staining to control for protein loading. Bars show mean ± SD (N = 3 biological replicates). **, P < 0.01 by two-way ANOVA with Sidak multiple comparisons test (vs. DMSO). Representative blots are shown in Supplementary Fig. S5A. B, HBS1L, IFRD1, and vinculin protein levels assessed by Simple Western in FOCAD isogenic MIAPACA2 cells after 48 hours of treatment with the indicated concentrations of TNG961. Representative images are from N = 2 biological replicates. C, ATF4 and vinculin protein levels assessed by Western blot in FOCAD isogenic MIAPACA2 cells after 48 hours of treatment with the indicated concentrations of TNG961. Tm, tunicamycin (positive control for ATF4 induction). Representative images are from N = 2 biological replicates. D, Spliced XBP1 (XBP1s) and actin protein levels assessed by Western blot in MIAPACA2 cells expressing a doxycycline (DOX)-inducible FOCAD cDNA (−DOX, FOCAD not expressed/FOCAD-null; +DOX, FOCAD expressed/FOCAD-reconstituted) after 72 hours of treatment with the indicated concentrations of TNG961. Representative images are from N = 2 biological replicates. E, qPCR analysis of CHOP, TRIB3, and GADD34 mRNA levels in FOCAD isogenic MIAPACA2 cells after 48 hours of treatment with the indicated concentrations of TNG961. Bars show mean ± SD (N = 4 biological replicates). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANOVA with Dunnett multiple comparisons test (vs. DMSO). ANOVA P values (FOCAD null): CHOP P = 0.0044, TRIB3 P < 0.0001, GADD34 P = 0.0016; ANOVA P values (FOCAD reconstituted): CHOP P = 0.4290, TRIB3 P = 0.0320, GADD34 P = 0.0108.

  • Open Access

    Figure 5 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 selectively impairs the viability of FOCAD-negative cells in vitro and inhibits the growth of FOCAD-negative tumors in vivo. A, Relative viability of FOCAD isogenic NCIH1755 cells after 7 days of treatment with the indicated concentrations of TNG961, measured by CellTiter-Glo. Data are mean ± SD (N = 3 biological replicates). B, Relative viability of FOCAD isogenic cell line pairs from the indicated parental models after 7 days of treatment with TNG961, measured by CellTiter-Glo. HAP1 and HeLa are endogenously FOCAD-positive, and isogenic pairs were generated by FOCAD knockout; NCIH1755, MIAPACA2, and MDA-MB-231 are endogenously FOCAD-negative, and isogenic pairs were generated by re-expression of full-length FOCAD cDNA. Selectivity was calculated as potency in FOCAD-positive cells divided by potency in FOCAD-negative cells. Data are mean ± SD (N = 3 biological replicates). C, Potency of TNG961 across a panel of endogenously FOCAD-negative and FOCAD-positive cell lines after 7 days of treatment (maximum concentration 3 µmol/L), measured by CellTiter-Glo (viability assay) and adjusted to free potency to account for serum protein binding (5%–20% across culture conditions). Cell lines with free potency above the maximum concentration tested are plotted at the top dose. Data are mean ± SD (N = 2 technical replicates per model). D, Plasma exposure of TNG961 after 7 days of twice-daily dosing in MIAPACA2 xenograft–bearing mice and corresponding tumor pharmacodynamics assessed by Western blot 12 hours after the last dose (HBS1L protein levels shown as a fraction of the vehicle control band intensity). E–H, Tumor volume over time in mice bearing xenograft tumors (N = 8 mice/arm) from the indicated models treated orally with the indicated doses of TNG961 twice daily for the indicated duration. Data are mean ± SEM.

  • Open Access

    Figure 7 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 shows in vivo activity in the PRMT5 inhibitor–refractory setting and inhibits the growth of cells harboring C-terminal FOCAD truncations. A, Mice bearing MIAPACA2 xenografts were treated orally twice daily with 60 mg/kg vopimetostat (TNG462) or 60 mg/kg TNG961. After 21 days (black arrow), treatment was continued as indicated (blue and gray) or switched from vopimetostat to TNG961 (red). Tumor volumes were measured by calipers (N = 8 mice/arm). Data are mean ± SEM. B, Schematic showing the tail-to-tail orientation of FOCAD and CDKN2A on chr9p21. C, Endogenous FOCAD truncations in MDA-MB-231, DAOY, and NCIH838 cells mapped by qPCR using probes tiled across the FOCAD locus. Black segments denote exons with confirmed expression; gray segments denote exons between a positive probe (black) and the first negative probe (end of bar). D, NCIH1755 cells were engineered to express HA-tagged FOCAD cDNA encoding the indicated C-terminal truncations. Relative viability after 7 days of TNG961 treatment was assessed by CellTiter-Glo. Data are mean ± SD (N = 2 biological replicates). E, Western blot confirming the expression of HA-tagged FOCAD truncations and the corresponding effects on SKIV2L stability. Representative images are from N = 2 biological replicates.

  • Open Access

    Figure S3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 selectively inhibits growth of FOCAD-negative cells

  • Open Access

    Figure S2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 has proteome-wide selectivity for HBS1L

  • Open Access

    Figure S1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers

    by Hilary E. Nicholson, Douglas A. Whittington, Frank J. Bruzzese, Katherine Lazarides, Lauren Catherine M. Martires, Matthew R. Tonini, Helena N. Jenkins, Minjie Zhang, Preksha Shahagadkar, Charlotte B. Pratt, et al.

    TNG961 is a CRBN-dependent HBS1L molecular glue degrader